Product
Epalrestat + Alpha Lipoic Acid
1 clinical trial
1 indication
Indication
Diabetic Neuropathy PeripheralClinical trial
A 3-arm, Open-label, Stratified Randomized Controlled Trial With Blinded End-point Assessment to EValuate A Nitric oxidE Generator (Nebivolol) as a diSease Modifying mediCatioN in Diabetic Peripheral NeuropathyStatus: Not yet recruiting, Estimated PCD: 2025-12-30